Anthem, Allure/RF, Allure Quadra/RF family of CRT-Ps
ABBOTT MEDICAL · Decision date Jul 21, 2026
What did the FDA approve?
FDA records P030035/S211 as a supplement to PMA P030035, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 21, 2026.
FDA approval order statement
approval for Merlin 2 Patient Care System (PCS) programmer support for the AVEIR Leadless Pacemakers.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 21, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P030035/S211
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NKE
- Decision code
- APPR
- Decision date
- Jul 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Abbott Medical
- Product code
- NKE
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P030035/S211 received
Application receipt date recorded by FDA.
P030035/S212 · Related supplement
Anthem, Allure/RF, Allure Quadra/RF family of CRT-Ps
P030035/S211 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P030035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Apr 24, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 15900 Valley View Ct., Sylmar, CA, 91335
Sources and methodology
- Original FDA record: P030035/S211
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



